ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,955.25
-0.47%
US Tech 100
20,574.80
-1.06%
다우존스 지수
43,621.16
0.37%
Bitcoin
88,424.54
-3.30%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. BioCryst Pharmaceuticals Inc (BCRX) 시세

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc (BCRX)

NASDAQ
8.28
-0.01
(-0.12%)
종가: 26 2월 6:00AM
15분 지연
8.28
-0.01
( -0.12% )
시간외 거래: 6:00AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
8.28
매수가
8.24
매도가
8.50
거래량
3,671,701
7.935 일간 변동폭 8.44
4.03 52주 범위 9.50
market_cap
1.715B
전일 종가
8.29
개장가
8.44
최근 거래 시간
160
@
8.28
(priorref)
마지막 거래 시간
06:08:00
재정 규모
US$ 30,222,308
VWAP
8.2311
평균 볼륨(3m)
2,533,694
발행 주식
207,132,571
배당수익률
-
주가수익률
-7.58
주당순이익(EPS)
-1.09
매출
331.41M
순이익
-226.54M

BioCryst Pharmaceuticals Inc 정보

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, ... BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.biocryst.com
본부
Wilmington, Delaware, USA
설립됨
-
BioCryst Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker BCRX. The last closing price for BioCryst Pharmaceuticals was US$8.29. Over the last year, BioCryst Pharmaceuticals shares have traded in a share price range of US$ 4.03 to US$ 9.50.

BioCryst Pharmaceuticals currently has 207,132,571 shares in issue. The market capitalisation of BioCryst Pharmaceuticals is US$1.72 billion. BioCryst Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.58.

BCRX 최신 뉴스

추가 뉴스

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
47 분 전
BCRX (-0.12%)

Form 8-K - Current report
Edgar (US Regulatory)
24 2월 2025
BCRX (-0.12%)

Form 8-K - Current report
Edgar (US Regulatory)
13 1월 2025
BCRX (-0.12%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-1.1-11.72707889139.389.57.9548932749.07749299CS
40.273.370786516858.019.57.5432582128.74262333CS
120.992513.61921097777.28759.56.9625336948.12433006CS
260.121.470588235298.169.56.84521901177.91967169CS
522.5845.26315789475.79.54.0327473766.72676869CS
156-8.3-50.060313630916.5818.64.0330523618.65495513CS
2605.83237.9591836732.4519.991.5841279738.26268604CS

BCRX - Frequently Asked Questions (FAQ)

What is the current BioCryst Pharmaceuticals share price?
The current share price of BioCryst Pharmaceuticals is US$ 8.28
How many BioCryst Pharmaceuticals shares are in issue?
BioCryst Pharmaceuticals has 207,132,571 shares in issue
What is the market cap of BioCryst Pharmaceuticals?
The market capitalisation of BioCryst Pharmaceuticals is USD 1.72B
What is the 1 year trading range for BioCryst Pharmaceuticals share price?
BioCryst Pharmaceuticals has traded in the range of US$ 4.03 to US$ 9.50 during the past year
What is the PE ratio of BioCryst Pharmaceuticals?
The price to earnings ratio of BioCryst Pharmaceuticals is -7.58
What is the cash to sales ratio of BioCryst Pharmaceuticals?
The cash to sales ratio of BioCryst Pharmaceuticals is 5.18
What is the reporting currency for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals reports financial results in USD
What is the latest annual turnover for BioCryst Pharmaceuticals?
The latest annual turnover of BioCryst Pharmaceuticals is USD 331.41M
What is the latest annual profit for BioCryst Pharmaceuticals?
The latest annual profit of BioCryst Pharmaceuticals is USD -226.54M
What is the registered address of BioCryst Pharmaceuticals?
The registered address for BioCryst Pharmaceuticals is 2711 CENTERVILLE ROAD, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the BioCryst Pharmaceuticals website address?
The website address for BioCryst Pharmaceuticals is www.biocryst.com
Which industry sector does BioCryst Pharmaceuticals operate in?
BioCryst Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ICCTiCoreConnect Inc
US$ 2.05
(70.85%)
2.19M
HCTIHealthcare Triangle Inc
US$ 0.6208
(59.59%)
4.86M
PITAHeramba Electric PLC
US$ 0.4896
(34.43%)
414.83k
ENVBEnveric Biosciences Inc
US$ 1.52
(27.73%)
1.49M
PCPremium Catering Holdings Ltd
US$ 0.959
(14.49%)
615
FLYWFlywire Corporation
US$ 14.50
(-17.80%)
69.82k
RETOReTo Eco Solutions Inc
US$ 0.8799
(-17.38%)
678.82k
VEROVenus Concept Inc
US$ 0.4501
(-16.68%)
6.61M
MTSRMetsera Inc
US$ 23.12
(-15.64%)
2.69k
XHGXChange TED Inc
US$ 0.96
(-12.73%)
19.81k
VEROVenus Concept Inc
US$ 0.4501
(-16.68%)
6.61M
LCIDLucid Group Inc
US$ 2.87
(9.96%)
6.47M
HCTIHealthcare Triangle Inc
US$ 0.6261
(60.95%)
4.87M
LRCXLam Research Corporation
US$ 80.70
(0.50%)
3.21M
SMCISuper Micro Computer Inc
US$ 44.70
(-1.82%)
2.36M

BCRX Discussion

게시물 보기
rosemountbomber rosemountbomber 1 일 전
What is this company doing?  No wonder Denner bailed.  
👍️0
Monksdream Monksdream 2 일 전
BCRX 10Q due MONDAY 2/24
👍️0
rosemountbomber rosemountbomber 1 월 전
What is going on here, stock price whipsawed from one day to the next. Doesn't seem like any rhyme or reason.
👍️0
Monksdream Monksdream 2 월 전
BCRX, under $8
👍️0
Monksdream Monksdream 4 월 전
BCRX under $10

👍️0
Monksdream Monksdream 7 월 전
BCRX under $8
👍️0
Monksdream Monksdream 10 월 전
BCRX new 52 week low
👍️0
Monksdream Monksdream 10 월 전
BCRX new 52 lo
👍️0
Monksdream Monksdream 10 월 전
BCRX new 52 week lo
👍️0
Monksdream Monksdream 11 월 전
BCRX under $10
👍️0
Monksdream Monksdream 1 년 전
BCRX 10Q 2/26
👍️0
Calcumad Calcumad 1 년 전
It is turning around. Just let the big guys manipulate it enough so they can collect from the shorting and then buy cheaper
👍️0
james kent james kent 2 년 전
when will it turn around?
👍️0
james kent james kent 2 년 전
when will it turn around?
👍️0
ttubular ttubular 2 년 전
Huge buys in AH
👍️0
VivaLasVegas VivaLasVegas 2 년 전
Why is this symbol now taking a digger with all the rest?
What did Stoney do or not do?
👍️0
ttubular ttubular 3 년 전
6:58a ET 8/4/2022 - Globe Newswire
BioCryst Resumes Enrollment in BCX9930 Clinical Program
Mentioned: BCRX
EQNX::TICKER_START (NASDAQ:BCRX), EQNX::TICKER_END BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

Clinical evidence and recent laboratory studies have informed the company's hypothesis that crystals form in the kidneys of some patients. The company believes that lowering the dose to 400 mg and ensuring adequate hydration will dilute the concentration of drug in the urine below the threshold where crystals can form.
👍️0
rosemountbomber rosemountbomber 3 년 전
Don’t have the link but apparently Denner sold a bunch of BCRX 05/16/2022.
👍️0
conix conix 3 년 전
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by stock analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports. They presently have a $13.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00. Barclays‘s price objective suggests a potential upside of 14.14% from the stock’s current price.

BCRX has been the subject of a number of other research reports. Piper Sandler restated an “in-line” rating and issued a $24.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 23rd. Evercore ISI lowered their target price on shares of BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Finally, Oppenheimer lowered their target price on shares of BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.09.
👍️0
Cosa Cosa 3 년 전
I guess it was perfect timing in a way...
👍️0
Cosa Cosa 3 년 전
I reduced my position here to buy more AUPH (facepalm)
👍️0
starkd748 starkd748 3 년 전
13.90s pullback yesss
👍️0
starkd748 starkd748 3 년 전
Overbought pullback in progress TA saves money
👍️0
Limey42 Limey42 3 년 전
You were saying? LMFAO!!!!!!!!
👍️0
game7alcs game7alcs 3 년 전
BCRX just on CNBC for large call volume action
👍️0
starkd748 starkd748 3 년 전
Burnt to a crisp rsi enjoy
👍️0
starkd748 starkd748 3 년 전
Lmfao the rsi is 100 pullback in progress
👍️0
ttubular ttubular 3 년 전
Understatement
👍️0
Limey42 Limey42 3 년 전
This company is a juggernaut!
👍️0
plexrec plexrec 3 년 전
Worldwide addressable market ??? Any estimate what kind of sales company is targeting ??? Totals ???? Rare diseases etc ????? TIA
👍️0
ezyE ezyE 3 년 전
Great buying opportunity.
Shouldn't be this low.
👍️0
easyrider1 easyrider1 3 년 전
What a complete manipulation to knock this down to get cheap stock. IMHO, the best low priced play in the market. The earnings report wil get this th $18 Total disregard for upgrades etc. this is a buying opportunity.
👍️0
easyrider1 easyrider1 3 년 전
Total joke to knock this down under $15 with all the positive news in the short term. Cashing in my soda bottles to buy more
👍️0
starkd748 starkd748 3 년 전
Might buy some options here
👍️0
easyrider1 easyrider1 3 년 전
Strongest day since the ill fated secondary announcement and we held most of the gains. Now we need volume.
👍️0
MZlu MZlu 3 년 전
I remember in recent weeks, we have seen some PR operations which I don't know if they were initiated by BioCryst:
- They won a prize for R&D
- They won a prize for marketing
- Barron's did a favorable mention of the Company
Looks like the big boys are shifting the narrative.
👍️0
easyrider1 easyrider1 3 년 전
First sign of life….someone realizes that this a buy
👍️0
Deano361 Deano361 3 년 전
Yeah been 18 months now and holding for me . I thin pnh results soon will help us
👍️0
easyrider1 easyrider1 3 년 전
I can’t believe that we are trending downward and broke $14. I keep buying a tad on each dip, but the dips are getting lower. I don’t understand what I’m missing with the breakout sales and potential for nearing profitability and real potential for a buyout.

This is still one of my favorite holdings but so disappointing since the Mgmt’s botched secondary attempt and lack of credible explanation.
👍️0
Deano361 Deano361 3 년 전
Yes two positive things going on . The new drug getting approvals and revenue and the pnh upcoming fast track trials
👍️0
Cosa Cosa 3 년 전
The sharp increase in revenue is what got my attention!
👍️0
Cosa Cosa 3 년 전
"Facepalm" I jinxed you guys.
👍️0
bhulkupk bhulkupk 3 년 전
Hi Cosa, welcome…
👍️0
Deano361 Deano361 3 년 전
Hi, been in since March/april 2020 from $3s. The key to this stock are upcoming 4Q results from PNH. PNH positive data makes this a $100 stock in 18 months IMO. Keep an eye on warrants and data.
👍️0
Cosa Cosa 3 년 전
Hello All, new here. Grabbed a little just to have in my portfolio to keep an eye on this. Looks like its been consolidating for almost 5 months! Still doing DD.
👍️0
easyrider1 easyrider1 3 년 전
Can’t believe with all the recent news especially appointment of Galson to the board and connections with Amgen that we’re not at $20 by now. The dip to the low $14’s was a gift.

More publications are suggesting that Bcrx is one off the best stock pics of the year. This is my favorite stock as I continue to accumulate…..doesn’t seem like there is anything but strong upside
👍️0
Deano361 Deano361 3 년 전
Well, it’s one of my few long 3 year stocks IMO . Started at $3 last year
👍️0
bhulkupk bhulkupk 3 년 전
Oh okay, so I can buy some for long term? Thanks in advance.
👍️0
Deano361 Deano361 3 년 전
It’s a quote from executive and it’s all about pnh for the future . Pnh is going to be Golden !!
👍️0
bhulkupk bhulkupk 3 년 전
How?
👍️0

최근 히스토리

NASDAQ
BCRX
BioCryst Pharmaceuticals
BOV
BIGE39
BlackRock Institutional ...
BOV
BEFG39
BlackRock Institutional ...
BOV
B2HI34R
BILL
BIT
P1R353
BNP Paribas Issuance
BIT
P1H4N9
BNP Paribas Issuance
BIT
UB93DN
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지